| Project/Area Number |
24390314
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
DOKI Yuichiro 大阪大学, 医学(系)研究科(研究院), 教授 (20291445)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKIGUCHI Shuji 大阪大学, 医学系研究科, 准教授 (00301268)
MIYATA Hiroshi 大阪府立成人病センター, 消化器外科, 副部長 (80362713)
KUROKAWA Yukinori 大阪大学, 医学系研究科, 助教 (10470197)
MIYAZAKI Yasuhiro 大阪大学, 医学系研究科, 助教 (00571390)
TAKADA Akihiro 大阪市立豊中病院, 消化器外科, 医員 (60597483)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2012: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
|
|---|
| Keywords | グレリン / 抗炎症作用 / 上部消化管手術 / 支持療法 / 化学療法 / 体重減少 / 胃切除 / 食道切除 |
|---|
| Outline of Final Research Achievements |
In preoperative chemotherapy in patients with esophageal cancer, ghrelin-administered group presented higher nutritional status and less side effect such as nausea and loss of appetite compared to the non-administrated group. In early postoperative phase after esophagectomy, ghrelin contributed to the reduction of systemic inflammatory response syndrome (SIRS) duration and inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6). The incidence of complications, especially pulmonary complications, was also significantly reduced by ghrelin administration. In addition, even for patients of more than one year after esophagectomy or gastrectomy, ghrelin increased calorie intake and body weight. In summary, ghrelin administration was feasible and effective as a supportive therapy in the multidisciplinary approach for gastrointestinal cancer patients.
|
